BEST SUPRATRADE STOCK PREDICT

Thursday, July 9, 2009

TradingMarkets 7 ETFs You Need to Know for Thursday

Sellers were especially aggressive in the financial sector, with the Financial Select Sector SPDRS ETF (XLF | Quote | Chart | News | PowerRating) losing more than 3% intraday. Country ETFs continued their pullbacks across the board, becoming increasingly oversold above their 200-day moving averages.

Here are 7 ETFs You Need to Know for Thursday

Soaring by more than 2% intraday, the CurrencyShares Japanese Yen Trust ETF (FXY | Quote | Chart | News | PowerRating) traded on Wednesday at levels not reached since February of this year.

Weakness in technology shares - especially semiconductors - helped push the ProShares UltraShort Semiconductor ETF (SSG | Quote | Chart | News | PowerRating) deeper into overbought territory below the 200-day moving average.

Trading at its highest levels since mid-March and increasingly overbought below the 200-day moving average, the ProShares UltraShort Financial ETF (SKF | Quote | Chart | News | PowerRating) gained more than 5% intraday on Wednesday.

TradingMarkets 7 Stocks You Need to Know for Monday

A slew of negative economic news kept shares trading in negative territory for most of the session. Consumer credit fell for the 4th straight month and the IMF forecast further contraction for 2009. Despite the rally-crushing news, bargain hunters were able to push the DJIA higher by +14.81 to 8178.41, the Nasdaq poked ahead by +1.00 to 1747.17 but the broad based S&P 500 failed to break the positive barrier slipping -1.47 to 879.56.

Here are 7 stocks you need to know about for Thursday:

Dow stalwart Alcoa (AA | Quote | Chart | News | PowerRating) posted 47 cents/share loss after the bell for the 2nd quarter. It's the first DJIA stock to report.

Today's Best Stocks To Trade - Click Here!

3Com (COMS | Quote | Chart | News | PowerRating) reports earning before the bell with an expected .04/EPS for the fiscal fourth quarter.

Jameson Resources(ASX:JAL).

Jameson Resources(ASX:JAL).

• A near term thermal coal production play.
• Valuation of $0.62 suggests significant upside!

Wise-owl.com recently placed a speculative buy on Jameson Resources (ASX:JAL).

WRGL Announces First Commercial Production Unit!

WRGL is slowly moving up, as more investors take notice. Once Wall St. takes notice, explosive break out is likely.

Last summer we saw crude prices near $150 per barrel before prices crashed. We might not see prices like that again this summer but I still think prices are going to go much higher than they are now.

This makes it the perfect timing to look at companies like WRGL.

WRGL has one mission: helping achieve effective energy independence for the United States.

Our huge dependency on foreign oil makes our nation so vulnerable.

And I don't think the alternative energy sources we have are that cost effective yet.

We need to find a solution and I believe that solution is companies like WRGL.

WRGL is dedicated to helping achieve effective energy independence for the United States using unconventional methods and new technologies for developing non-traditional hydrocarbon deposits.

WRGL's first enterprise centers around the use of an innovative, environment-friendly technology to extract oil from tar sand/tar shale in the western United States.

Most people don't know that from these tar sands we can extract a lot of oil!

Did you know that Canada gets about one-third of its oil from the tar sands buried in northern Alberta?

WRGL has announced the acquisition of two separate licenses for American Resource Petroleum Corporation's (“ARPC”) oil sand and oil shale extraction processes plus a contract to recover oil on property controlled by ARPC in Utah, with proven recoverable oil reserves in excess of 125 million barrels!

Few people know that Utah has the richest tar sands deposits in the United States.

Eastern Utah and western Colorado contain more oil than Saudi Arabia!

These deposits and the surrounding lands in eastern Utah are the most accessible and highest grade oil sands deposits in the world.

WRGL's acquisition of the ARPC technologies gives the company one of the world's most advanced and economical recovery systems for oil sand and oil shale extraction.

American Resource Petroleum Corporation's bitumen extraction process is a continuous flow non-heated process, concerned with solution treatment separation of bitumen from oil sands.

Process additives and mechanical devices allow for a higher percentage collection of the bitumen oils, with rates above 99%. It produces a higher quality bitumen oil containing more of the light petroleum ends. It recovers clean sand that can be sold or replaced where mined. It allows for a higher quality of the re-cycled process additives that will be re-used in the continuous flow process and it results in the elimination of environmentally unacceptable tailing ponds.

These attributes allow for a less expensive process than a batch or heat treated process or any heat exchanged application. The process also allows for the recycling of the process water.

This extraction process is one of the world's most advanced economical recovery systems for oil sand and oil shale extraction!

Imagine how big WRGL could become using this technology in Utah!

Utah's tar sand deposits contain 14 to 15 billion barrels of measured oil in place, with an additional estimated resource of 23 to 28 billion barrels.!

Most of the world's oil reserves are concentrated in the Middle East, and about two-thirds are controlled by OPEC members.

Oil price shocks and price manipulation by OPEC have cost our economy dearly.

I believe it is obvious that we need companies like WRGL!

Please do your due diligence and consult with a financial professional.

More information on WRGL is available at their website: http://www.wrgl.net

Wednesday, July 8, 2009

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases - (MobiWire)

July 8, 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases - (MobiWire)

Last Trade: $52.23
Change: 0.00
Open: $N/A
High: $N/A
Low: $N/A
Volume: 5176130

Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. Superiority was demonstrated for both delaying the time to the first on-study Skeletal Related Events (SREs)(fracture, radiation to bone, surgery to bone, or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and delaying the time to the first-and-subsequent SREs (hazard ratio 0.77, 95 percent CI: 0.66, 0.89). Both results were statistically significant.
Overall, the incidence of adverse events and serious adverse events was consistent with what has previously been reported for these two agents. Of note, osteonecrosis of the jaw (ONJ), which had not been observed in previously reported Phase 3 studies with denosumab, was seen infrequently in both treatment groups. There was no statistically significant difference in the rate of ONJ between the two treatment arms. Infectious adverse events were balanced between the two treatment arms, as was overall survival and the time to cancer progression.

"We are extremely pleased with the outcome of this important study, which shows that denosumab can reduce or delay the serious complications of bone metastases in breast cancer patients better than the current standard of care, and with a favorable benefit/risk profile," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These results underscore the importance of the RANK Ligand pathway in bone disease, and offer the promise of improved care for patients with advanced breast cancer. We look forward to reviewing the results from a second Phase 3 study of denosumab effects in advanced cancer patients later this year."

Bone metastases, the spread of tumors to the bone, are a serious concern for advanced breast cancer patients, with incidence rates as high as 75 percent. When cancer spreads to the bone, the growing cancer cells weaken and destroy the bone around the tumor. This damage can result in a number of serious bone complications, collectively called SREs.

Full efficacy and safety data will be submitted for presentation at an upcoming medical meeting in the second half of this year.

Study Design

This was an international Phase 3, randomized, double-blind study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced breast cancer. Patients enrolled in the study were randomized in a one-to-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks as per the labeled use.

In clinical trials testing new medications for bone metastases, treatment success has been measured by whether the bone complications, or SREs, caused by the tumor are reduced or delayed. The primary and secondary endpoints of the denosumab bone metastases studies use a composite endpoint of four SREs - fracture, radiation to bone, surgery to bone, and spinal cord compression - to measure the effectiveness of denosumab versus Zometa.

The primary endpoint was to evaluate if denosumab is non-inferior to Zometa with respect to the first on-study SRE in patients with advanced breast cancer and bone metastases. Secondary endpoints were to evaluate if denosumab was superior to Zometa with respect to the first on-study SRE, as well as first-and-subsequent on-study SREs, and to assess the safety and tolerability of denosumab compared with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Prevalence

Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(1) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(2), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients.

With bone metastases the growing cancer cells weaken and destroy the bone around the tumor. The damage the tumor has caused to the bone can result in a number of serious complications, collectively called skeletal related events (SREs). These include fracture of a bone, radiation to bone, surgery to bone, or spinal cord compression. All are serious complications for advanced cancer patients.

The economic burden of U.S. patients with bone metastases is significant and was estimated to be $12.6 billion last year.(3) Patients with bone metastases who experience an SRE incur significantly higher medical costs compared with those who do not experience an SRE.(4)

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of July 7, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

ZOMETA is a registered trademark of Novartis Oncology.

Dryships (DRYS) : Upgraded to Outperform at CSFB; $8 target - (MobiWire)

July 8, 2009
Dryships (DRYS) : Upgraded to Outperform at CSFB; $8 target - (MobiWire)

Last Trade: $4.90
Change: 0.00
Open: $N/A
High: $N/A
Low: $N/A
Volume: 478819

Credit Suisse is upgrading Dryships (NASDAQ: DRYS) to Outperform (previously Underperform) and increasing their target price to $8 (previously $5). Firm believes DRYS rig assets are being ignored by investors. While they expect oil prices to remain volatile, the recent oil price surge should help DRYS secure contracts for its speculative drillships which should in-turn help DRYS secure financing on its two un-financed drillships. While the timing of any new rig contracts remains uncertain they expect DRYS to fix 1-2 rigs on long term contracts later this year.

- They caution DRYS is not for the faint of heart and concerns remain about future equity issuances. DRYS raised $1.1 billion over the last 6 months (more than quadrupling its share count) and while highly dilutive it put DRYS balance sheet on stable ground. It is possible DRYS may tap the equity markets later this year, but do not expect it barring an acquisition, as they expect its shipyard to partially defer this years’ rig installment payments.

- Two Potential Catalysts for DRYS – Good and Bad. The positive catalyst for DRYS would be a fixture(s) for its newbuilding drillships. The negative catalyst would be a dilutive transaction for existing shareholders – this could be an equity issuance or a cancellation of existing newbuildings that results in payments of cash or shares to the selling party.

- Dry Bulk Freight Rates Softening– But Expectations are Low. Shipping is a demand driven story and the recent surge in freight rates has been driven by China’s thirst for iron ore. While CSFB expects Chinese iron ore imports to tail off in the back half of the year a pick up in demand from Other Asia or Europe could help off-set a potential slowdown in China.

Baltic Dry Index Off YTD High, But…
With the Baltic Dry Index trading over 3,000 and closer to its year to date high (4,291) than low (773), the firm expects the BDI to move lower heading into summer as port congestion in China unwinds, newbuildings are delivered, and China pulls back on its iron ore imports. Over the last few years DRYS has exhibited a strong correlation to the BDI – however, more recently the relationship between DRYS and the BDI has broken down. Over the last 6 months DRYS has exhibited a negative correlation to the BDI. This is not overly surprising given the volatility in the equity markets combined with DRYS ATM equity issuances in which DRYS raised roughly $1 billion in equity in at the market transactions.

Increasing Target Price to $8 (previously $5)
The $8 target price represents 60% upside potential from yesterday’s close. The $8 target price is based on our 2010 EBITDA estimate of ~$585 million and a ~6.5x EV/EBITDA multiple. O6.5x 2010 EBITDA multiple is a blended average of dry bulk comps (6.0x- 7.0x) and offshore driller comps (5.0x-6.5x). Following the completion of the last ATM equity issuance we estimate net debt at $1.5 billion and a share count of 258 million. Additionally, CSFB's $8 target price represents a 30% premium to DRYS NAV. DRYS dry bulk comps are trading at premiums to NAV ranging from 10% to over 100%.

They are increasing their 2009 EPS to $1.15 (previously $1.08) and 2010 EPS estimate to $1.09 (previously $1.01). The 2009 EPS revision was driven by increases to day rate estimates for the Panamax spot fleet. They expect the Panamax spot fleet to average roughly $16,000/d for the full year 2009.

Symphony Technology Group and Elliott Associates Announce Proposed Acquisition of MSC.Software

July 8, 2009
Symphony Technology Group and Elliott Associates Announce Proposed Acquisition of MSC.Software - (MobiWire)

Last Trade: $6.75
Change: 0.00
Open: $N/A
High: $N/A
Low: $N/A
Volume: 3454800

Symphony Technology Group (STG), a leading private equity firm, and Elliott Management Corp., a $14 billion private investment firm, today announced that affiliates of STG have entered into a definitive agreement with MSC.Software Corporation (MSC) to acquire all of MSC's outstanding shares in a one-step all-cash merger transaction valued at approximately $360 million. Under the terms of the agreement, MSC's stockholders will receive $7.63 in cash for each share of MSC common stock, representing approximately a 13% premium to the closing price per share of MSC's stock prior to this announcement and approximately a 24% premium compared to the 90-trading day trailing average price per share.
"MSC's offerings are the clear market leading simulation solutions with proven track records of delivering compelling value to customers. MSC has a long history of driving innovation in the design simulation space for multiple industries. Symphony's mission is to be a partner in helping to build great companies and in enabling growth through innovation, so we are very pleased to have the opportunity to build upon the strong franchise that the MSC team has developed over the past 45 years," said Dr. Romesh Wadhwani, Chief Executive Officer and Managing Director of Symphony Technology Group.

"We are very pleased to have facilitated this transaction," said Jesse A. Cohn, Portfolio Manager at Elliott. "This will allow MSC to continue to deliver innovative solutions in the simulation software sector. As significant equity holders in MSC, we will maintain our ownership alongside STG, which has a strong track record of building outstanding software companies."

MSC.Software's Board of Directors has approved the merger agreement and are recommending that stockholders adopt the agreement. In connection with the transaction, stockholders representing approximately 14% of the outstanding shares of MSC, including the company's largest stockholder, Elliott, and all of the company's directors and executive officers, have entered into voting agreements to vote in favor of the transaction. Elliott also has committed to provide debt and equity financing to help finance the transaction. Wells Fargo Foothill, part of Wells Fargo & Company (NYSE: WFC), and CapitalSource have committed to provide senior debt financing.

The MSC transaction is subject to customary closing conditions, including approval of MSC's stockholders and regulatory approvals. This transaction is expected to close near the end of the third quarter of 2009.

Shearman & Sterling LLP served as legal counsel to STG; Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to Elliott; and Davis Polk & Wardwell LLP served as legal counsel to MSC.

About Symphony Technology Group

Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformative expertise to enable its companies to deliver maximum value to their clients to retain and attract the best talent and to achieve best in class business performance. All STG companies are expected to grow through innovation. STG's current portfolio consists of nine global companies.

About Elliott

Elliott's two funds, Elliott Associates, L.P. and Elliott International, L.P., together have more than $14 billion of assets under management. The funds' investors include institutions, foundations, endowments, pensions, high net worth individuals, and family offices. The 32-year-old trading firm is one of the oldest of its kinds under continuous management.

About MSC.Software Corporation

MSC.Software Corporation (Nasdaq: MSCS) is a global leader of simulation solutions that help companies make money, save time and reduce costs associated with designing and testing manufactured products. MSC.Software works with thousands of companies in hundreds of industries to develop better products faster by utilizing information technology, software, services and systems. MSC.Software employs more than 1000 people around the world. For additional information about MSC.Software's products and services, please visit www.mscsoftware.com.

Media Contact:
Carol Sacks
Tenor Communications
+1 650.520.8261
carol@tenorcom.com

Bull Alert - New 52 Week High for Helix Wind

Helix Wind (HLXW) closed out another strong trading session yesterday, hitting a high of $3.07. As we have stated many times to our members, we strongly believe that this small-cap Alternative Energy stock, could quite easily eclipse analyst expectations and trade well over their target price of $5.74 per share.

Helix has been on a tear of late, consistently breaking through new 52 week highs and creating new support levels, like they have done this week at $3.03. After breaking through $3.00 per share last week, we feel the next resistances point for Helix Wind (HLXW) is $3.30 to $3.40 per share, and we strongly believe the company will surpass the analysts expectations।

http://www.youtube.com/watch?v=zkJiNNLOuow

http://www।helixwind.com/en/

http://www.youtube.com/watch?v=q9flSPAdOLk

Top 10 Analyst Upgrades and Downgrades

These are the top ten pre-market analyst upgrades, downgrades, and initiations we have seen from Wall Street analysts this Wednesday morning with about two and a half hours until the market opens:

Air Products (APD) Raised to Buy at KeyBanc.
Chattem (CHTT) Cut to Hold at Jefferies.
Citrix Systems (CTXS) Cut to Perform at Oppenheimer.
Freeport-McMoRan (FCX) Raised to Buy at Citigroup.
Photronics (PLAB) Raised to Buy at UBS.
Qualcomm (QCOM) Started as Outperform at Morgan Keegan.
SAP (SAP) Raised to Buy at Jefferies.
Southern Copper (PCU) Raised to Hold at Citigroup.
STMicro (STM) Raised to Buy at BofA/Merrill.
Starwood Hotels (HOT) Cut to Underperform at Baird.

JON C. OGG
JULY 8, 2009

5 Cheap Stocks to Buy Now

Go Long on Cheap,
High Beta Stocks

If you owned or purchased cheap stocks at the beginning of the year, you have been rewarded handsomely for your risk taking. Many of the stocks that were summarily crushed during the credit crisis last fall bounced hard off lows reached in November and March.

In fact, some have doubled or tripled in a very short period of time. But that should come as no surprise to investors — historically, owning cheap stocks at the end of a recession can deliver big returns. That certainly has been the case so far this year, and the likelihood of more gains is quite promising. Ask any professional trader which approach is working best of late, and you will hear: "go long on cheap, high beta stocks and do so aggressively."

In my Top 5 Penny Stocks to Buy Now, I put together five cheap stocks that I thought would do well in 2009. "Well" is an understatement. Three of the five stocks have nearly doubled in value or more. TriQuint Semiconductor (TQNT) is up 151% since mid-December. Only one of the five picks is down in the period — with a mere loss of 10%.

Now, with much action in the space and so much potential money to be made by speculating on cheap stocks, I'm in the process of launching an exciting new service for investors called Penny Stock Winners that focuses entirely on these low-priced gems।

Cheap Stock 1:
Star Bulk Carriers (SBLK)

If you're interested in cheap stocks, take a look at the dry bulk shipping sector. The global recession has decimated shipping rates at a time when capacity is on the rise. The double whammy of falling demand and increased supply has resulted in stocks in the group falling hard.

Names including Star Bulk Carriers (SBLK) lost significant value in 2008. But sometimes the harder they fall, the harder they rise. Bulk shippers have been huge winners since last March with some stocks going up by three or four times their price at the bottom.

While we have yet to see a big improvement in the global economy, improvement could propel these stocks to another triple or more. SBLK priced shares for the public at the peak of the market at a $15 level.

Those levels can be reached again as a new economic cycle begins।

Cheap Stock 2:
StemCells, Inc. (STEM)

The overwhelming election of Democrats in all houses of government is expected to be quite positive for the stem cell space. Under the previous administration, efforts to fund research proved to be elusive. That is not the case today. Companies like StemCells, Inc. (STEM), who are racing to bring this exciting area of research to market, now have friends in Washington.

After the initial euphoria, stem cell stocks have settled back toward the lows reached prior to the election. In a market that has been cruel to any sort of speculation, investing in hope has been a tough sell. The market, though, is inefficient here. Those willing to speculate have the potential for huge gains.

Bringing a drug to market from stem cell research may not be profitable today, but things are stirring in the space. This week General Electric (GE) announced a deal with fellow stem cell player, Geron (GERN). Gentlemen, start your engines. GERN was up big on the news with STEM moving a modest 2% higher.

At $1.70 per share, STEM is incredibly cheap given the potential. Don't let fear in the market keep you away from risk-taking. Some, including myself, suggest that is exactly what you should be doing।

Cheap Stock 3:
Sirius XM Radio (SIRI)

If you can't beat them, join them.

Sirius (SIRI) is doing just that by teaming up with Apple (AAPL) to create an application for the iPhone that will stream Sirius XM content to subscribers. And so there goes one of the big arguments against SIRI. Critics claimed that the iPod would destroy the need for satellite radio. Wrong. With Apple and Sirius teaming up, the device is now a friend of Sirius.

It hasn't been an easy path for SIRI. Huge expenses associated with building its business saddled the company with debt that nearly brought about its demise. Shares of SIRI fell to a just a few pennies in anticipation of bankruptcy. Fortunately, improvement in the debt market and a white knight in the form of Liberty Media allowed SIRI to refinance maturing debt. A recent debt sale went better than expected.

Now, as a pure monopoly play, good times are just ahead। My question is: How can you not own this stock?

Cheap Stock 4:
Quicksilver (ZQK)

We're not even half way through summer, but retailers are already salivating for the all-important back-to-school shopping season. And that makes now the perfect time to place your bets on Quicksilver (ZQK).

This formerly edgy company has struggled with declining sales and huge losses that weighed heavily on the balance sheet. Recently, ZQK obtained debt financing but at a prohibitive cost even while eliminating near-term liquidity concerns. The company is clearly betting on a big fall sales season as it will need better than the $2.8 million in profits earned in the most recent period.

If the bet is a winner, investors will see the stock quickly rebound. Although the risk is high, so too could be the reward.

I'd buy ZQK in advance of the back-to-school rush।

Cheap Stock 5:
TriQuint Semiconductor (TQNT)

TriQuint Semiconductor (TQNT) was trading at just over $2 per share at the end of 2008. That was before the entire semiconductor sector exploded as investors speculated on the dawn of a new product replacement cycle.

Even better for TQNT has been the growth of the smartphone. TQNT is a supplier of component parts that have incredible revenue generating potential for the company, despite being commodity-based. That explains the big move in the stock to date, but more gains are coming.

In any other economic environment, TQNT is a $20 stock. Instead, the company trades for just over $5 per share. The company is a momentum play, and I look for it to post impressive revenue and profit growth as the smartphone spreads like wild fire.

IX Energy Lands Third New Contract in Two Weeks

IX Energy Lands Third New Contract in Two Weeks

What do the following dates and places have in common? June 22, Ann Arbor Michigan; June 25, Saginaw Michigan; July 7, New Orleans. Those dates come pretty close together, and all have a number of things in common.

Those dates relate to contract awards for solar rooftop arrays being installed as part of the US Government's initiatives to deploy new green technologies. Two of the locations are VA hospitals- one is a High School.

And, there's one more thing. All three contracts to design and manage the installations were awarded toOTC Journal following IX Energy. That's three new contract announcements all in a stretch of two weeks, which is pretty impressive when you consider this is just starting.

Earlier today, IXEH announced it has been awarded a contract to design and install a 28kW system at Warren Easton High School in New Orleans as part of The New Orleans Solar School Initiative.

In this case, the project is being funded by a grant from Nike- that's right- they are Just Doing It. In all, there will be solar installations of 4 high schools in New Orleans- three more to be announced.

The projects serves the dual purpose of both energy savings and demonstrating a practical, working model of solar technology to the students. The installation will also provide jobs in the New Orleans area.

As covered in past editions- once again- IXEH's exclusive relationship with US Government owned Unicor has yielded another contract to design and install a solar system.

I don't know how you see it, but in my view three new contract signings over a period of two weeks is very impressive, and can only lead one to believe there is more to come and substantial growth out in front of IXEH. The Unicor solar panel facility is just coming online, so these contracts are just the beginning of a large series of US Government opportunities.

After all, $1 billion has been allocated for improvements to the VA System alone. That business will continue to flow for a couple of years, and is just getting started. IXEH has already been awarded two contracts to design and install solar arrays for VA Hospitals.

We've now established the company is moving forward rapidly. Now, how about the stock? Going the opposite way. In fact, as I write the coverage of today's event, the stock is making a new low.

The stock is trading at about $.20, which I believe is a bargain basement steal. I estimate their relationship with Unicor probably has an intrinsic value of $50 million when one considers the number of future contracts to be awarded by the US Gov't. Three new contracts have been signed in the last two weeks alone. The whole market value of the company at these levels is about $12 million.

I don't know where the bottom is, or what it will take to turn the stock around. However, I do know this company is risky, but it is certainly headed in the right direction.

We started with this one at $.57, with an SSL of $.45. So far, a miserable performance on the stock side, and a great performance on the company side.

With the stock cut in half from my original SSL, now might be the time to consider pouncing on this oversold, bargain basement level. Put in a tight stop, and see if you get a bounce on today's news. I don't know why the stock is trading so poorly- clearly there is more supply than demand today. If that dynamic changes, and the stock bounces, you might be in position for a great trade.

If you are holding this stock at higher levels and didn't get out, think longer term and recognize the company is doing its part by landing these Government sponsored solar contracts.

Here is today's news in its entirety:

IX Energy Partners With Advanced Green Technologies to Build 28kW Solar Array

7/7/2009 10:16:25 AM - Market Wire

First School to Receive Solar in New Orleans Solar School Initiative

NEW YORK, NY, Jul 07, 2009 (MARKETWIRE via COMTEX News Network) --

IX Energy Holdings, Inc. (OTCBB: IXEH), a company engaged in the development of solar power and other renewable energy solutions for the federal government and commercial markets, announced that it is partnering with Advanced Green Technologies (AGT), a subsidiary of Advanced Roofing, to build a 28kW rooftop solar array at Warren Easton High School in New Orleans as part of the New Orleans Solar School Initiative. Advanced Roofing is the prime contractor on the installation.

The New Orleans Solar School Initiative, which aims to roll out solar to four New Orleans schools, is a project being led by Winrock International, Entergy, and Nike. Entergy, a local New Orleans utility, is taking the lead in the investment on the project to deliver clean energy back into the community of New Orleans. The project was initially made possible by a grant from Nike through proceeds it generated through a transaction of carbon offsets registered with Winrock's American Carbon Registry.

The 28kW grid-tied system, covering 6,634 sq. feet, will produce 37,000 kWh of solar energy each year and can be expanded to as much as 125kW. AGT will be responsible for the design and integration of the system while IX Energy will provide the electrical install, materials and balance of system. The project, scheduled to start in the first week of July, is expected to be complete by August.

Steve Hoffmann, CEO of IX Energy, said, "We commend groups like this on their leadership and continued proactive stance in developing and supporting renewable energy projects such as the New Orleans Solar School Initiative. It creates a valuable learning environment for students in the community to see how solar energy can be implemented, where the school becomes an example for teaching the importance of conserving energy. In addition, we are pleased to be working with AGT, whose products are well suited for this project."

AGT will also provide an interactive solar monitoring system to measure the daily, weekly, monthly and lifetime totals of energy generated in kWh. The visual display also tracks the impact the solar system is having on the environment in tangible terms including gallons of gas, dozens of light bulbs and pounds of coal, all off-set by solar energy.

"Renewable energy has become a global necessity," stated Michael Kornahrens, President of AGT. "Providing the products and installation is only the beginning. Educating children and adults alike on the importance of solar energy and how a photovoltaic system works is extremely important. Our solar data monitoring system enables us to look at the overall production of the solar system and show the environmental offsets made directly from the use of solar energy."

About Advanced Green Technologies

Advanced Green Technologies, an innovative renewable energy solutions provider, procures building-integrated renewable energy products. With 25 years of experience in the commercial roofing and building industry, AGT provides the products, designs and support for installations of the most advanced, cost effective, and efficient green solutions for customers. For more information on Advanced Green Technologies renewable energy solutions, contact 954 735 2641 or visit www.AGT.com.

About IX Energy Holdings, Inc.

Founded in 2006, IX Energy, Inc., the wholly owned subsidiary of IX Energy Holdings, Inc. is a renewable energy services company engaged in the design, marketing, development and financing of solar power systems and other renewable energy solutions to federal and commercial customers. In June, 2008, the Company entered into a non-exclusive agreement with Federal Prison Industries, Inc. ("UNICOR"), under which UNICOR provides the labor for assembly and production of solar panels for the Company, and the Company sells the solar panels to Federal customers. The agreement has a term of five years. For more information about IX Energy Holdings visit www.ixenergy.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements with the terms "believes," "belief," "expects," "intends," "anticipates," "will" or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.

Company Contacts Corporate Communications Aspire Clean Tech Communications, Inc. Todd M. Pitcher 760-798-4938 Rubenstein Investor Relations Tim Clemensen 212-843-9337

SOURCE: IX Energy Holdings

Checks Remain the Same

This is a delayed, partial version of the Whisper Report prepared before the beginning of trading on Monday, July 6, 2009

As we begin the second half of 2009, it is important to take a look at where we are most likely heading. As we have been saying for the last couple of months, we expect the recession to end once General Motors begins production at its recently closed plants but the end-of-the-recession trade was likely over once the May employment report was announced.

The S&P 500 ended 2008 at 903.25, which was 18.24 times trailing earnings. Since World War II, we have yet to see the S&P 500 trade at a lower PE multiple the year a recession ended than it did the previous year. We believe a trailing PE multiple of 19.0 to 21.5 is a reasonable target for the end of 2009 assuming a double-dip recession does not occur in the first-half of 2010, which is also a reasonable possibility.

Standard & Poors tells us that the consensus top-down operating earnings estimates for the S&P 500 is $43.03 per share. However, given the recent estimate raises at Morgan Stanley, Bank of America-Merrill Lynch, and others, we believe $50 per share is the true expectation at the moment. The next couple of weeks will say a lot about how reasonable this expectation is and where estimates are likely to move next, but at the moment this suggests a year-end target for the S&P 500 in the 950 to 1,075 range.

How the stock market gets from here to there is likely the bigger issue and the topic getting the most attention from nearly every technician recently is the formation of a head and shoulders pattern. This suggests downside risk for the S&P 500 to the 875 support line and a potential break. So, in the short-term, this is the pattern we need to watch most closely heading into second quarter earnings season and it implies we need to look for short opportunities at least to start out the season.

From a sector view, most data points have changed little over the past several weeks. Consumer Discretionary stocks continue to manage inventories well with upside risk from a better-than-expected economy. Technology tracks well from both an inventory basis with demand also holding up well. Financials have macro tailwinds with among the most profitable spreads on record and the possibility of inflation increasing the written-down assets on the balance sheets.

The recent surprise has been the Consumer Staples. At the beginning of the year, as the group was preparing their budgets, production was apparently cut too far and production is currently rising to meet demand. Our informal checks suggest the production isnt too the point of hiring back laid off workers, but many production lines are running well above the targets set at the beginning of the year just after the financial crisis started and many workers within this sector are seeing overtime. Meanwhile, material costs are declining, the U.S. Dollar has weakened, and few have lowered the prices that were raised this time last year before Lehman Brothers collapsed.

On the other hand, the inflation trade continues to appear much too early for the cycle and, in fact, continue to see weakening trends with lower demand and rising inventories. The data points for the Industrials, the Materials, and Energy suggest these continue to be the sectors with the most downside risk at the moment and only the weak U.S. Dollar is supporting the stocks.

While we believe the overall risk to the stock market for the year is to the upside and believe the Financials have the most wind at their backs, we are less confident about the group at the beginning of this earnings season than we were last quarter. Weve yet to have a meaningful rally in the overall market without the Financials rallying, so while the S&P 500 is forming a head and shoulders pattern, the Financials are failing to break the trend line set since the markets high in October 2007.

We are more than a week away before the major Financials release earnings, but even though checks are positive for the group if we are going to trade the stocks going into their earnings release in anticipation of an earnings beat, the 875 line needs to hold as support for the S&P 500 and the trend line for the Financials needs to be broken.

The past several weeks since the Presidents decision to give unions priority to assets over debt holders in the General Motors and Chrysler bankruptcies the U.S. Dollar has been the primary focus for the markets. At the moment, we are seeing long-term professional currency traders go long the U.S. Dollar on the view that we are still in the early stage of a multi-year bull market for the Dollar and we have professional macro traders bet on a long-term bear market for the Dollar for political reasons. We are not comfortable assuming either side will win out in the long-term and, therefore, are only short-term Dollar traders and anytime there is Dollar strength, we want to short the Industrials, Materials, and Energy sectors.

At the moment, we see more upside risk to the Dollar. When we watch the Dollar, we focus our attention on the Euro the anti-Dollar and sentiment continues to suggest small traders are extremely bullish the Euro and commercial traders are adding to their short positions. We will always take the side of the commercial traders in this scenario and, to support this view, we have a stochastic cross at a lower-high for the Euro.

On the fundamental side, the Eurozone continues to ease while Australia, Switzerland, New Zealand and other countries have been publicly discussing the damaging impact of the weak U.S. Dollar on their respective economies and have either taken steps to weaken their own currencies or have suggested they plan to cut rates and/or take additional easing steps.

At the same time, we are in a seasonally strong period for the U.S. Dollar as Japanese summer bonuses tend to leave Japan for the U.S. Furthermore, the Chinese cycle suggests there is downside risk to the inflation trade from economic data points and from a U.S. Dollar story. As we have mentioned previously, China tends to see a peak in production during the month of April, restock inventories in May, and, starting in June, begin a period of buying U. S. Treasuries. Perhaps China will divert more capital into its own stimulus plans, but we tend to believe this is more likely priced into the market rather than the possibility that its previous cycle trends will resume and that means upward pressure on the U.S. Dollar and downward pressure on commodities. It is our view that, political issues aside, the relative value of the U.S. Dollar vs. the rest of the globe that is lagging in terms of economic activity as well as central bank easing policies. We also believe that the stock market does not have to depend on Dollar weakness to rally. However, in order to be truly bullish now that the end-of-the-recession trade is over, we believe the sectors that are seeing favorable data points need to outperform those that have rallied simply because of the weak Dollar. This week and early next week, as the initial earnings releases for each sector come in, should provide the basis for trading during the remaining weeks of earnings season.

One recent data point that we have neglected to discuss thoroughly is our Earnings Expectations oscillator shown on the front page of our website and on the first page of this report. Analysts are conservative by nature and when they, as a group, become increasingly optimistic about the possibility of a near-term upside earnings surprise from the companies they follow to the point that more expect an earnings beat than expect an earnings miss, it tends to be a positive indicator for the overall market. We have not had a buy signal since the recession began in late 2007, but data checks have been positive and we have had a handful of buy signals over the past few weeks.

The market could be a sign that there is too much optimism going into earnings seasons and we are setting up form disappointing results, which is where we are leaning, but that is not the signal this indicator has given us in the past. Therefore, we have to view the recent stock market activity as a consolidation ahead of another move to the upside until we are shown otherwise. Consequently, we are giving the 875 support area the benefit of the doubt and will look to be buyers near this level, but will wait for overall price action and earnings news to confirm before we become too aggressive.

Alcoa

There was a tremendous amount of buying of shares of Alcoa (AA) in mid-March and this has created a support base that likely needs to be respected, but the stock is currently a long way from this point on a percentage basis and we have yet to see any positive data points for the company. In fact, all data points suggest production continues to outpace sales so that decade-plus inventory levels continue to climb. To make matters worse, Chinese production of the metal appears to be picking up, which means inventories levels are likely to continue to climb and that is very bearish for the stock in the longer-term.

The stock generally trades at 12.4 times forward estimates, which suggests the stock should be trading closer to $5 than its current $10 range and, unless Alcoa gives evidence that trends are going to change soon, the stock is likely to trade below most of the recent target prices established by the analysts, which are in the $8 to $9 range.

For the quarter, the consensus estimate is a loss of $0.34 per share and the Earnings Whisper number is a loss of $0.40 per share.

Checks Remain the Same

This is a delayed, partial version of the Whisper Report prepared before the beginning of trading on Monday, July 6, 2009

Breaking News: Odyssey Oil & Energy, Inc. (OTCBB: OOGI)

Odyssey Oil & Energy, Inc. (OTCBB: OOGI)

Odyssey Acquires 51% of H-Power International (Pty) Ltd

JOHANNESBURG, South Africa -- Odyssey Oil & Energy, Inc. (OTCBB: OOGI) is pleased to announce the acquisition of 51% of H-Power International (Pty) Ltd.

The acquisition gives Odyssey the exclusive worldwide rights over the patented Hybrid Battery Technology.

"This revolutionary technology allows Odyssey to pursue the storage of alternative green energy including solar and wind power," commented Arthur Johnson, President.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, included or incorporated by reference herein relating to management's current expectations of future financial performance, continued growth, changes in economic conditions or capital markets, and changes in customer usage patterns and preferences are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

WEMU Awarded $6 Million Solar Contract

Worldwide Energy and Manufacturing Announces Korean PV Certification and New South Korean Contract Valued at $6 Million
On Tuesday July 7, 2009, 11:58 am EDT

Worldwide Energy and Manufacturing USA, Inc. (OTC.BB:WEMU - News), a U.S.-based China manufacturing company specializing in products for customers in the industries of solar energy, aerospace, wireless telecommunications, medical equipment and automotive, today announced it has received Korean certification for its solar module products and, subsequently, has been awarded a new South Korean contract for photovoltaic (PV) modules amounting to $6 million because of this obtained International Standards (IEC) certification.

Worldwide Energy's Chief Executive Officer Jimmy Wang stated: "This contract validates our solar market research and proves there is a good demand for our Amerisolar panels in South Korea. With our approved Korean and UL certifications, which allow faster access to our customers, and our technologically advanced solar modules, we expect this new order, together with our first order in the U.S. announced a month ago, will mark the beginning of many more orders for us in the U.S. and Korean markets. Based on our market analyses, we expect to generate millions of dollars in sales in these markets this year."

The solar energy industry continues to see strong growth. According to Lux Research, the global solar energy market is expected to double in the next five years from $36 billion in 2008 to $70 billion in 2013. The European Photovoltaic Industry Association (EPIA) expects global incremental solar power installation to grow from 5.6 GW in 2008 to 12.6 GW in 2013. Much of the growth is expected to occur in the U.S. market, fueled by recent government incentives for utility companies to develop PV projects.

Worldwide's mono and polycrystalline modules feature a two-bus bar cell design which maximizes the cell's light absorbing surface area, giving the modules more consistent performance. Their solar modules also have a weather-resistant frame constructed of aluminum alloy for endurance in rugged weather conditions and are given a double oxidation coating for additional protection against the elements, providing for longer-lasting, more durable modules.

Worldwide currently sells its advanced solar modules under the brand name, "AmeriSolar," in eight countries, including Germany, Italy, Switzerland, Portugal, France, Spain, Australia, United States and South Korea.

"We continue to focus our sales and marketing efforts on increasing our customer base for our solar modules in Europe and other parts of the world, including North America and South Korea. Our solar brand AmeriSolar continues to gain recognition and widespread acceptance in the global marketplace," added Mr. Wang.

About Worldwide Energy and Manufacturing USA, Inc.

Worldwide Energy and Manufacturing USA, Inc. ("Worldwide"), headquartered in South San Francisco, California, is a 15-year-old engineering-oriented firm specializing in photovoltaic (PV) panel, mechanical, electronics and fiber optic products manufacturing. The company's worldwide customer base includes the industries of solar energy, wireless telecommunications, aerospace, automobiles and medical equipment. Subsidiaries include: Worldwide Energy and Manufacturing Ningbo (Solar factory) Co., Ltd, Shanghai Intech Electro Mechanical Products Co. Ltd., Shanghai Intech Electronics Manufacturing Co. Ltd., Shanghai Intech Precision Mechanical Products Manufacturing Co. Ltd. and Shanghai Intech Electric and Electronics Co., Ltd., located in Shanghai and Ningbo, China.

For further information on Worldwide Energy and Manufacturing USA, Inc., please visit http://www.wwmusa.com. You may register to receive Worldwide Energy and Manufacturing USA, Inc.'s future press releases or request to be added to the Company's distribution list by contacting John Ballard.

CIA: Make a World of Difference


July 6, 2008

©2008 BLACK ENTERPRISE, All Rights Reserved About Us \| Contact Us \| Privacy Policy *The views expressed in the above ad are those of the advertiser and not those of Black Enterprise or BlackEnterprise.com 130 Fitth Avenue, New York, NY 10011

Tuesday, July 7, 2009

Strong Buy Signal: Endeavor Power (EDVP)

Strong Buy Signal: Endeavor Power (EDVP)	2nd week - July 2009

Projection: Buy EDVP up to $2 before price
goes over $10 after Initial Growth Phase

Endeavor Power is currently expanding its producing well portfolio by 40% per month. I project that the company will have over 150 producing wells by the end of current initial phase.

Endeavor Power’s current estimated resource is 1 million barrels of oil = $70+ million in value. I project that this resource estimate will increase by $30 million per every 10 wells completed.

Endeavor currently trades below $2 and could attain up to $450,000,000 in resource value. I project that early shareholders will be protecting EDVP profits above $10 and holding the rest at much higher prices.

Thursday, July 9, 2009

TradingMarkets 7 ETFs You Need to Know for Thursday

TradingMarkets 7 Stocks You Need to Know for Monday

Wednesday, July 8, 2009

Top 10 Analyst Upgrades and Downgrades

Go Long on Cheap,High Beta Stocks

Cheap Stock 1:Star Bulk Carriers (SBLK)

Cheap Stock 2:StemCells, Inc. (STEM)

Cheap Stock 3:Sirius XM Radio (SIRI)

Cheap Stock 4:Quicksilver (ZQK)

Cheap Stock 5:TriQuint Semiconductor (TQNT)